First Clinical Study Using HCV Protease Inhibitor Danoprevir to Treat Naive and Experienced COVID-19 Patients

Hongyi Chen; Zhicheng Zhang; Li Wang; Zhihua Huang; Fanghua Gong; Xiaodong Li; Yahong Chen; Jinzi J. WU

The laboratory results revealed lymphopenia (0.62 ×10 9 /L) and elevated platelet (322 ×10 9 /L) ( Table 3) .  On February 22, 3 days after receiving danoprevir boosted by ritonavir treatment, the patient didn't show abnormal symptoms or vital signs. The lower lobe of bilateral lung showed decreased GGO and patch-shaped areas compared to the previous image on February 20, indicating partial absorption ( Figure 2B ). The RT-PCR results of nasal swab became negative. These results indicated the patient had a quick response to the treatment of danoprevir boosted by ritonavir, along with interferon nebulization.  On February 24, 5 days after receiving danoprevir boosted by ritonavir treatment, the GGO and patch-shaped areas in both lungs significantly decreased in density and scale ( Figure 2C ) compared to the previous image on February 22. And the RT-PCR results of nasal swab were repeatedly negative on February24 and February 26.  On February 28, Patient #1 was given the last dose of danoprevir boosted by ritonavir, along with interferon nebulization. Since she met all four discharge standards described in Methods section, the patient was discharged from the hospital on the same day.